Moderna announced an agreement in principle with the Australian Government to build a state of the art messenger RNA (mRNA) vaccine manufacturing facility in Victoria, Australia.
Article continues below
r>
The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vaccines in development for respiratory viruses. Moderna and the Australian government are committed to finalize the agreement.
“We are committed to public health and while we are still responding to this pandemic, we also want to ensure we and society learn from it. As Moderna expands internationally, we are pleased to bring local mRNA manufacturing to Australia. We believe that this sustainable national business model will have global impact and implications.â€
Moderna is committed to working with governments, health care professionals and other key stakeholders to meet the challenges of the COVID-19 pandemic and future pathogens. Moderna expects to invest in a state of the art manufacturing facility for the production of mRNA vaccines with the collaboration of the Commonwealth and Victorian Governments.
The collaboration aims to provide Australians with access to a domestically manufactured portfolio of mRNA vaccines against respiratory viruses, including COVID-19, seasonal influenza, respiratory syncytial virus (RSV) and potential other vaccines, pending licensure. Moderna expects that up to 100 million vaccine doses could be produced in Australia each year.
The facility is intended to also be activated on an urgent basis to support Australia with direct access to rapid pandemic response capabilities. The Company is in discussion with other governments about potential collaborations built on a similar model.
“We are excited to expand our presence and continue our long term collaboration with the Australian and Victorian Governments,†said Michael Azrak, Moderna’s General Manager of Australia. “We look forward to completing the necessary discussions and starting work to develop onshore mRNA manufacturing capability here in Australia.†■